Cathie Wood's ARK buys CRISPR, sells Roku and DraftKings stock

Cathie Wood’s ARK ETFs have reported their daily trades for Tuesday, August 26th, 2025, with significant activity in biotech and tech stocks. The largest trade of the day was the purchase of 165,874 shares of CRISPR THERAPEUTICS AG (NASDAQ:CRSP), valued at approximately $8.98 million, through its ARKK ETF. This acquisition is part of a growing trend, as ARK also bought shares of CRISPR THERAPEUTICS on Monday, indicating a bullish stance on the gene-editing company.

On the selling side, ARK offloaded a substantial number of shares in DRAFTKINGS INC (NASDAQ:DKNG) and ROKU INC (NASDAQ:ROKU) through its ARKK ETF, with the sales amounting to $6.04 million and $6.61 million, respectively. The move away from these stocks follows a pattern of reduction, particularly for ROKU, which ARK has been selling consistently over the past week.

Another major buy was in INTELLIA THERAPEUTICS INC (NASDAQ:NTLA), with ARK purchasing 191,705 shares for around $2.18 million through its ARKK ETF. Similar to CRISPR, INTELLIA has seen increased interest from ARK, with purchases made on multiple days in the past week, signaling a strong conviction in the gene-editing space.

The trades also included smaller sales in COINBASE GLOBAL INC (NASDAQ:COIN) and SHOPIFY INC (NYSE:SHOP) through its ARKW ETF, with the transactions valued at approximately $597,312 and $588,680, respectively. These sales continue the trend of ARK reducing exposure to certain tech stocks, as seen with previous transactions last week.

Investors following ARK’s movements will note the ETF’s strategic shifts, with a clear focus on increasing positions in biotech companies specializing in CRISPR technology while reducing holdings in specific tech and entertainment companies. These trades reflect ARK’s ongoing strategy to capitalize on disruptive innovation and technology in various sectors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.